ロード中...
Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma
OBJECTIVE: Iodine-131-labelled meta-iodobenzylguanidine ((131)I-mIBG) therapy is an established treatment modality for relapsed/refractory neuroblastoma, most frequently administered according to fixed or weight-based criteria. We evaluate response and toxicity following a dosimetry-based, individua...
保存先:
| 出版年: | Nucl Med Commun |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Lippincott Williams & Wilkins
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4819901/ https://ncbi.nlm.nih.gov/pubmed/26813989 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MNM.0000000000000470 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|